FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387406711> ?p ?o ?g. }

• W4387406711 abstract "Therapeutic options for ulcerative colitis (UC) have increased since the introduction of biologics a few decades ago. Due to the wide range of biologics available, physicians have difficulty in selecting biologics and do not know how to balance the best drug between clinical efficacy and safety. This study aimed to compare the efficacy and safety of biologics in treating ulcerative colitis.In this study, eight electronic databases (PubMed, Web of Science, Cochrane, Embase, Sinomed, China National Knowledge Infrastructure, Chongqing VIP Information, and WanFang Data) were searched to collect eligible studies without language restrictions. Retrieved 1 June 2023, from inception. All articles included in the mesh analysis are randomised controlled trials (RCTs). The inclusion of drugs for each outcome was ranked using a curved surface under cumulative ranking (SUCRA). Higher SUCRA scores were associated with better outcomes, whereas lower SUCRA scores were associated with better safety. This study has registered with PROSPERO, CRD42023389483.Induction Therapy: Among the biologic therapies evaluated for induction therapy, vedolizumab demonstrated the highest efficacy in achieving clinical remission (OR vs daclizumab, 9.09; 95% CI, 1.01-81.61; SUCRA 94.1) and clinical response. Guselkumab showed the lowest risk of recurrence of UC (SUCRA 94.9%), adverse events resulting in treatment discontinuation (SUCRA 94.8%), and serious infections (SUCRA 78.0%). Maintenance Therapy: For maintenance therapy, vedolizumab ranked highest in maintaining clinical remission (OR vs mesalazine 4.36; 95% CI, 1.65-11.49; SUCRA 89.7) and endoscopic improvement (SUCRA 92.6). Infliximab demonstrated the highest efficacy in endoscopic improvement (SUCRA 92.6%). Ustekinumab had the lowest risk of infections (SUCRA 92.9%), serious adverse events (SUCRA 91.3%), and serious infections (SUCRA 67.6%).Our network meta-analysis suggests that vedolizumab is the most effective biologic therapy for inducing and maintaining clinical remission in UC patients. Guselkumab shows promise in reducing the risk of recurrence and adverse events during induction therapy. Infliximab is effective in improving endoscopic outcomes during maintenance therapy. Ustekinumab appears to have a favorable safety profile. These findings provide valuable insights for clinicians in selecting the most appropriate biologic therapy for UC patients." @default.
• W4387406711 created "2023-10-07" @default.
• W4387406711 creator A5002232208 @default.
• W4387406711 creator A5002861610 @default.
• W4387406711 creator A5011927717 @default.
• W4387406711 creator A5045769854 @default.
• W4387406711 creator A5046339629 @default.
• W4387406711 creator A5068088670 @default.
• W4387406711 creator A5070820936 @default.
• W4387406711 creator A5090048840 @default.
• W4387406711 date "2023-10-06" @default.
• W4387406711 modified "2023-10-11" @default.
• W4387406711 title "Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis" @default.
• W4387406711 cites W1486205675 @default.
• W4387406711 cites W1515157499 @default.
• W4387406711 cites W1617328014 @default.
• W4387406711 cites W1981090098 @default.
• W4387406711 cites W1984705525 @default.
• W4387406711 cites W2001775809 @default.
• W4387406711 cites W2009841271 @default.
• W4387406711 cites W2020640954 @default.
• W4387406711 cites W2023078169 @default.
• W4387406711 cites W2036186700 @default.
• W4387406711 cites W2062766962 @default.
• W4387406711 cites W2064485014 @default.
• W4387406711 cites W2092863985 @default.
• W4387406711 cites W2102897127 @default.
• W4387406711 cites W2104391214 @default.
• W4387406711 cites W2112768046 @default.
• W4387406711 cites W2160619682 @default.
• W4387406711 cites W2162805528 @default.
• W4387406711 cites W2169559894 @default.
• W4387406711 cites W2171297959 @default.
• W4387406711 cites W2237475190 @default.
• W4387406711 cites W2289887585 @default.
• W4387406711 cites W2616235887 @default.
• W4387406711 cites W2970843227 @default.
• W4387406711 cites W2976362764 @default.
• W4387406711 cites W2976731348 @default.
• W4387406711 cites W3001717534 @default.
• W4387406711 cites W3080017516 @default.
• W4387406711 cites W3091680144 @default.
• W4387406711 cites W3093715541 @default.
• W4387406711 cites W3126111424 @default.
• W4387406711 cites W3214731670 @default.
• W4387406711 cites W4205253993 @default.
• W4387406711 cites W4223588491 @default.
• W4387406711 cites W4226191244 @default.
• W4387406711 cites W4226297186 @default.
• W4387406711 cites W4281647041 @default.
• W4387406711 cites W4282048809 @default.
• W4387406711 cites W4283391702 @default.
• W4387406711 cites W4285164505 @default.
• W4387406711 cites W4285809753 @default.
• W4387406711 cites W4294613078 @default.
• W4387406711 cites W4312211968 @default.
• W4387406711 cites W4318478359 @default.
• W4387406711 cites W4318762665 @default.
• W4387406711 cites W4318777090 @default.
• W4387406711 cites W4360600172 @default.
• W4387406711 cites W4377008398 @default.
• W4387406711 doi "https://doi.org/10.1186/s12876-023-02938-6" @default.
• W4387406711 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37803294" @default.
• W4387406711 hasPublicationYear "2023" @default.
• W4387406711 type Work @default.
• W4387406711 citedByCount "0" @default.
• W4387406711 crossrefType "journal-article" @default.
• W4387406711 hasAuthorship W4387406711A5002232208 @default.
• W4387406711 hasAuthorship W4387406711A5002861610 @default.
• W4387406711 hasAuthorship W4387406711A5011927717 @default.
• W4387406711 hasAuthorship W4387406711A5045769854 @default.
• W4387406711 hasAuthorship W4387406711A5046339629 @default.
• W4387406711 hasAuthorship W4387406711A5068088670 @default.
• W4387406711 hasAuthorship W4387406711A5070820936 @default.
• W4387406711 hasAuthorship W4387406711A5090048840 @default.
• W4387406711 hasBestOaLocation W43874067111 @default.
• W4387406711 hasConcept C126322002 @default.
• W4387406711 hasConcept C197934379 @default.
• W4387406711 hasConcept C2776207728 @default.
• W4387406711 hasConcept C2777138892 @default.
• W4387406711 hasConcept C2778715236 @default.
• W4387406711 hasConcept C2779134260 @default.
• W4387406711 hasConcept C2780479503 @default.
• W4387406711 hasConcept C71924100 @default.
• W4387406711 hasConceptScore W4387406711C126322002 @default.
• W4387406711 hasConceptScore W4387406711C197934379 @default.
• W4387406711 hasConceptScore W4387406711C2776207728 @default.
• W4387406711 hasConceptScore W4387406711C2777138892 @default.
• W4387406711 hasConceptScore W4387406711C2778715236 @default.
• W4387406711 hasConceptScore W4387406711C2779134260 @default.
• W4387406711 hasConceptScore W4387406711C2780479503 @default.
• W4387406711 hasConceptScore W4387406711C71924100 @default.
• W4387406711 hasIssue "1" @default.
• W4387406711 hasLocation W43874067111 @default.
• W4387406711 hasLocation W43874067112 @default.
• W4387406711 hasOpenAccess W4387406711 @default.
• W4387406711 hasPrimaryLocation W43874067111 @default.
• W4387406711 hasRelatedWork W2039430653 @default.
• W4387406711 hasRelatedWork W2221971298 @default.
• W4387406711 hasRelatedWork W2530401429 @default.

• next